Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Jan;124(1):113-119.
doi: 10.1007/s00702-016-1630-6. Epub 2016 Oct 7.

A single dose of L-DOPA changes perceptual experiences and decreases latent inhibition in Parkinson's disease

Affiliations
Randomized Controlled Trial

A single dose of L-DOPA changes perceptual experiences and decreases latent inhibition in Parkinson's disease

Orsolya Györfi et al. J Neural Transm (Vienna). 2017 Jan.

Abstract

Despite the well-known neuropsychiatric side effects of dopaminergic medications, the possible subjective psychotomimetic effects of a single dose of L-DOPA in newly diagnosed, drug-naïve patients with Parkinson's disease (PD) are not known. To investigate this question, we used a visual search task for latent inhibition (LI), the Community Assessment of Psychic Experiences (CAPE) scale, and visual analog scales for psychotomimetic effects (perception, relaxation, and dysphoria) in 28 de novo PD patients before (off) and after (on) the adminstration of L-DOPA and in 25 matched healthy control individuals. Results revealed increased LI in PD-off and decreased LI in PD-on relative to the control subjects. After the administration of L-DOPA, we observed a significant decline in LI in PD. L-DOPA also enhanced perceptual experiences (changes in subjective feelings in thinking, time perception, and mental "highness"). Greater reduction in LI was associated with enhanced perceptual experiences. These results suggest that a single dose of L-DOPA has a significant psychotomimetic effect, which is associated with decreased LI, a behavioral marker of psychosis-like experiences.

Keywords: L-DOPA; Latent inhibition; Parkinson’s disease; Psychosis; Psychotomimetic effects.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4 - PubMed
    1. Neurology. 1967 May;17(5):427-42 - PubMed
    1. Acta Psychiatr Scand. 2006 Jul;114(1):55-61 - PubMed
    1. JAMA. 2014 Apr 23-30;311(16):1670-83 - PubMed
    1. Psychopharmacology (Berl). 2003 Sep;169(3-4):314-20 - PubMed

Publication types

LinkOut - more resources